Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuroblastoma breakpoint family, member 6 pseudogene (NBPF6 pseudogene, ENSG00000277655), is a non-protein-coding genomic element in humans. It is classified as a pseudogene, meaning it is homologous to the functional NBPF6 gene but contains disablements (such as frameshifts or premature stop codons) that prevent the production of a functional protein product[1][2][6][7]. The NBPF gene family has expanded significantly in the human genome and is notable for high sequence similarity among its members, including both genes and pseudogenes. While some pseudogenes may be transcribed or have regulatory roles, there is no evidence that this specific pseudogene encodes any functional RNA or protein, nor is it implicated directly as a drug target or biomarker. The accurate identification of pseudogenes is important to prevent misannotation and PCR amplification errors in genetic studies[6]. Pseudogenes like this one are generally not considered therapeutic targets, and their functions—when present—are mainly regulatory or evolutionary[2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuroblastoma breakpoint family, member 6 pseudogene (NBPF6 pseudogene).